|
|
|||
|
||||
OverviewThis book opens up the world on private equity investment in one of the hottest industries – Biotechnology. The book describes how Europe has fallen behind the US due to under-investment and bad management by the VCs who control the companies. Detailed analysis shows why it is in VCs' interests to damage the very companies they invest in. Full Product DetailsAuthor: W. BainsPublisher: Palgrave Macmillan Imprint: Palgrave Macmillan Edition: 1st ed. 2009 Weight: 0.301kg ISBN: 9781349303816ISBN 10: 134930381 Pages: 220 Publication Date: 01 January 2009 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand We will order this item for you from a manufactured on demand supplier. Table of ContentsReviews'With this well-referenced book Dr Bains has filled an important lacuna within the literature on European biotech VC [venture capital] financing with an accessible primer for MBA students particularly those researching biopharma and VC business cases and for students undertaking specialist, industry-focused, post-graduate courses.' Gerhard Symons, Pharmaceutical Executive Europe Author InformationWILLIAM BAINS is an academic and entrepreneur with experience in research, company creation and venture capital. He has founded four biotechnology companies, helped found and finance another ten, and is internationally recognized both as an innovator in biotechnology and a translator of innovation into business. He has written over 100 papers and teaches on innovation and entrepreneurship at Cambridge University, UK. Tab Content 6Author Website:Countries AvailableAll regions |
||||